Local Institution - 201

Toronto, Ontario M5G 2M9

0 studies enrolling now · 7 studies all time

What they study most

Isocitrate Dehydrogenase, Leukemia, Myeloid, Leukemia, Myeloid, Acute, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes

Studies at this site

• A Safety and Preliminary Efficacy Study of CC-99282, Alone and in Combination With Anti-lymphoma Agents in Participants With Relapsed or Refractory Non-Hodgkin Lymphomas (R/R NHL) — Running, not enrolling
• A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes — Stopped early
• Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia — Stopped early
• An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation — Completed
• A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma — Stopped early
• A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma — Completed
• A Safety and Efficacy Study of CC-90009 Combinations in Subjects With Acute Myeloid Leukemia — Stopped early